Numeric Investors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,737,705 shares of the biopharmaceutical company’s stock after acquiring an additional 206,000 shares during the period. Gilead Sciences accounts for approximately 1.7% of Numeric Investors LLC’s portfolio, making the stock its 4th biggest holding. Numeric Investors LLC owned 0.21% of Gilead Sciences worth $193,775,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Keel Point LLC boosted its stake in shares of Gilead Sciences by 0.4% during the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares during the last quarter. West Oak Capital LLC lifted its position in Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the period. First Heartland Consultants Inc. lifted its position in Gilead Sciences by 0.4% during the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the period. Arrow Financial Corp lifted its position in Gilead Sciences by 0.3% during the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock worth $1,258,000 after buying an additional 45 shares during the period. Finally, Westover Capital Advisors LLC lifted its position in Gilead Sciences by 0.8% during the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 46 shares during the period. 76.23% of the stock is currently owned by institutional investors and hedge funds.
GILD has been the topic of several recent analyst reports. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Berenberg Bank reiterated a “buy” rating and set a $86.00 target price (up from $79.00) on shares of Gilead Sciences in a research report on Sunday, August 20th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price on the stock. in a research report on Monday, August 28th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Finally, Credit Suisse Group set a $79.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $85.22.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period last year, the business posted $2.75 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.76%. Gilead Sciences’s payout ratio is currently 23.69%.
In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 458,486 shares of company stock worth $35,190,731. Company insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/04/numeric-investors-llc-buys-206000-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.